ArticleMolecular biotechnology2000
Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.
Article in Molecular biotechnology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals.Clinical & translational immunology · 2024Article
- Who wins the combat, CAR or TCR?Leukemia · 2023Review
- T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.Scientific reports · 2022Article
- Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.Frontiers in immunology · 2021Review
- Editing of Endogenous Genes in Cellular Immunotherapies.Current hematologic malignancy reports · 2020Review
- Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.Journal of clinical immunology · 2012Article
- Effective transduction of primary mouse blood- and bone marrow-derived monocytes/macrophages by HIV-based defective lentiviral vectors.Journal of virological methods · 2006Article
- Quantitative imaging of the T cell antitumor response by positron-emission tomography.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant retroviruses are efficient vectors for introducing genes into many mammalian cell types. They are useful in the context of clinical as well as experimental applications, owing to the ability to generate high-titer and helper-free viral stocks. Retroviral vectors are especially appropriate for the transduction of primary lymphocytes, because gene transfer is stable and mediated by nonimmunogenic vectors. Stable integration in chromosomes of cells undergoing clonal expansion ensures that the foreign genetic material will be faithfully transmitted to the cells' progeny. However, oncoretroviral vectors derived from murine leukemia viruses (MLV) require target cell division to integrate. Here we review factors that determine retroviral-mediated gene transfer efficiency in primary T-lymphocytes, in particular, T-cell activation status, viral receptor expression, and culture conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.